FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) Files An 8-K Other Events
Item 8.01 Other Events.
issued a press release announcing that the first patient has been
dosed in the Phase I portion of the Phase I/II clinical trial of
FCX-007, the Companys gene-therapy candidate for the treatment of
Recessive Dystrophic Epidermolysis Bullosa. A copy of the press
release is filed herewith as Exhibit 99.1 and is incorporated by
reference herein.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press Release dated February 23, 2017
|
About FIBROCELL SCIENCE, INC. (NASDAQ:FCSC)
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults. FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) Recent Trading Information
FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) closed its last trading session 00.000 at 0.680 with 161,841 shares trading hands.
